id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
105,,,,,,,,,,,,,,,2024-05-13T12:18:58+06:00,BSH - H12301312741,Right,Nab-pacli,2024-03-18,6.0,"Pt received 1st line chemotherapy with AC > T from to 26.11.2022> Post Adjuvant
Evaluation with PET scan showed Bone mets
2nd line chemotherapy with Gemcitabine + Carboplatin (D1, D8) advised from India, At BSHL, this patient
has received Cycle 1 Day 8 with Gemcitabine + Carboplatin on 22.02.2023. Cycle 6 Day 8 with Gemcitabine
+ Carboplatin received on 19.06.2023. Cycle 11 with Zoledronic acid is due on 14.12.2023. (C10 given
outside)
Reviewed from TMH, 3rd line ChT due to PD with Oral Capecitabine 500mg > PD , SO changed to
Halaven, Cycle 4 Day 1 is due on 19.02.2024, Cycle 15 Zoclast is due on 18.04.2024 > PD (Bone &
Primary) > Started 3 weekly Nab-pacli for 6 cycle as per TMC from 18.03.24. C2 due on 08.04.24",2024-03-08,,2024-04-08,,2024-03-08,,,Breast,101,Upper middle class,BSBSC-240000101,AFSANA,1739416116,1981-11-04,Female,,,,,Dr Ferdous Ara Begum,BSH,2.0,3rd Line,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,C50.4- Upper-outer quadrant of breast,Breast,Right,,,Progressed,Alive,PD,,,,,,,,,,,,,,,,,,,,,
316,,,,,,,,,,,,,,,2024-06-15T12:55:01+06:00,BSH - H12301312741,Right,Nab-pacli,2024-03-18,6.0,"Pt received 1st line chemotherapy with AC > T from to 26.11.2022> Post Adjuvant
Evaluation with PET scan showed Bone mets
2nd line chemotherapy with Gemcitabine + Carboplatin (D1, D8) advised from India, At BSHL, this patient
has received Cycle 1 Day 8 with Gemcitabine + Carboplatin on 22.02.2023. Cycle 6 Day 8 with Gemcitabine
+ Carboplatin received on 19.06.2023. Cycle 11 with Zoledronic acid is due on 14.12.2023. (C10 given
outside)
Reviewed from TMH, 3rd line ChT due to PD with Oral Capecitabine 500mg > PD , SO changed to
Halaven, Cycle 4 Day 1 is due on 19.02.2024, Cycle 15 Zoclast is due on 18.04.2024 > PD (Bone &
Primary) > Started 3 weekly Nab-pacli for 6 cycle as per TMC from 18.03.24. C2 due on 08.04.24",2024-03-08,,2024-04-08,,2024-03-08,,,Breast,101,Upper middle class,BSBSC-240000101,AFSANA,1739416116,1981-11-04,Female,,,,,Dr Ferdous Ara Begum,BSH,2.0,3rd Line,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,C50.4- Upper-outer quadrant of breast,Breast,Right,,,Progressed,Alive,PD,,,,,,,,,,,,,,,,,,,,,
